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therapeutic strategies addressed to these pts. At first it has 
become evident that any age-cut-off adopted to identify 
“elderly pts” ( > 65 yo, > 75 yo or even > 85 yo) has intrinsic 
limitations because geriatric pts are an extremely 
heterogeneous group with respect to their general health 
status. Second, a comprehensive geriatric assessment is 
needed to stratify and weigh the spectrum of 
dysfunctions present at old ages in order to select pts 
suitable for treatment (with standard protocol or with 
adapted ones). Several instruments and screening tools are 
proposed in the literature aiming at evaluate the 
vulnerability of elderly cancer pts: from complex and time 
consuming procedures to more easy to apply ones and to self-
administered questionnaires based on self-assessment of a 
short list of items. Finally elderly pts should be evaluated 
during and after their cancer treatments in order to detect 
signs and symptoms related to potential complications due to 
the treatment itself in order to eventually modulate it 
accordingly. 
Brachytherapy (BT) is an attractive treatment option for 
elderly cancer patients and this is especially true for prostate 
and gynaecological malignancies. The International Society of 
Geriatric Oncology (SIOG) Radiotherapy Task Force has 
reviewed the current best practice and priorities for research 
in radiation oncology for elderly patients with cancer. It has 
been stated that life expectancy and comorbidities should 
influence the selection criteria for prostate BT and that an 
international consensus is needed to define the subset of 
geriatric pts for prospective evaluation of BT acknowledging 
that a specific literature on BT for this group of cancer pts is 
virtually non-existent. Interestingly enough the same paper 
addresses the issue of BT (vaginal Brachytherapy, VBT) for 
postoperative irradiation of pts diagnosed with Endometrial 
cancer (ECa) in the Intermediate to High Risk Group. The 
PORTEC-2 Trial has found no significant differences between 
external beam RT and VBT in pts > 60 years old in terms of 
local or distant recurrence rates, but with a reduced toxicity 
and improved quality of life making VBT the adjuvant 
treatment option in this setting. Furthermore, the last up-
date of the Guidelines of the European Association of Urology 
(EAU) devotes a specific chapter to the Management of 
Prostate Cancer in Older Men, recognizing that this is 
a specific subgroup of PCa pts emphasizing that, according to 
published results from the US Surveillance Epidemiology and 
End Results (SEER) database, 71 % of PCa-related deaths 
occur in men aged ≥ 75 years. Surprisingly enough, after a list 
of rather generic recommendations about the need of a 
comprehensive baseline evaluation of life expectancy, 
comorbidities and health status, BT is not even mentioned in 
the paragraph devoted to the treatment of localized 
disease…On the contrary, the recently published Updated 
recommendations of the working party on the management 
of PCa of the SIOG, clearly states that BT “can be a suitable 
option for older men with PCa”, but any further details is 
given concerning the profile of the “suitable” pts. 
In conclusion, the general picture of the management of 
older pts with PCa or gynaecological malignancies is rapidly 
changing: particular attention is nowadays reserved to this 
subset of pts. Specific and details guidelines are still lacking 
but the oncological community is aware of the importance of 
a tailored approach that has to take into account a correct 
evaluation of the baseline profile of the pt before any 
treatment can be proposed.    
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Experimental microdosimetry is performed with TEPC (Tissue 
Equivalent Proportional Counter) that are able to measure 
the stochastic of radiation interaction with micrometric 
sensitive volumes. To measure ionizations produced in 
microscopic site with a macroscopic volume, TEPC are filled 
with low-pressure gas. At Legnaro National Laboratories of 
INFN new TEPC have been developed that are able to 
measure high intensity therapeutic beams. They are called 
mini-TEPC because of their small dimensions of the sensitive 
volume. Moreover, miniaturization involves also the external 
dimensions since the counter is inserted in a titanium sleeve 
of 2.7mm external diameter. Mini-TEPCs have been tested 
under different fields. With proton beams, they showed that 
is possible to assess the RBE of proton beam by using a proper 
weighting function.  
It is possible to perform microdosimetry at nanometric level, 
at least down to 25nm, with an avalanche confinement TEPC. 
An Italian research project called MITRA is developing this 
kind of detector for ion beams.  
Finally, in the world there are only three operative 
nanodosimeters. They measure the track structure of the 
beam: two of them are able to measure the track structure 
due to the beam core and the penumbra. The BioQuaRT 
project compared the responses of the three nanodosimeters. 
The three nanodosimeters are very different as well as their 
outputs in terms of ICSD (Ionization Cluster Size 
Distributions). However, the sum distribution Fk versus M1 of 
the three devices forms an almost perfect universal curve, 
and shows a saturation effect like radio-biological cross 
sections as a function of LET. 
Results will be presented.  
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Monte Carlo simulations are commonly used in radiobiology or 
medical applications for evaluating the energy deposition of 
ionizing radiation in biological targets. Nevertheless, trying 
to predict the earlier radio-induced biological effects in a 
cell population starting from an accurate description of the 
energy deposition at their origin needs the development of 
dedicated simulation tools. The first requirement of these 
simulation tools is their capability to calculate the track 
structure of the ionizing radiation with nanometric precision. 
Indeed, the nanometer scale corresponds to molecular 
dimensions and in particular to the scale of the DNA molecule 
that is the main target for which radiation damages can be 
linked to mutagenic or even lethal effects. Several dedicated 
simulation tools for this purpose have been developed in the 
last decades, following a mechanistic approach for the 
simulation of early radiation-induced biological effects. In 
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the mechanistic approach, the first track structure simulation 
(or physical stage) is followed by the simulation of the 
physico-chemical and the chemical stages that allows 
evaluating indirect damage in the DNA molecule created by 
reactive oxygen speciesproduced by the irradiation in its 
vicinity. 
Following a similar approach, a new multi-scale simulation 
tool is being developed in the frame of the BioQuaRT project. 
However, the philosophy of this project slightly differs from a 
pure mechanistic simulation aimed at calculating radiation-
induced biological effects. Our approach integrates an 
important experimental characterisation of ion tracks at 
micrometric and nanometric levels that can be reproduced by 
the multi-scale simulation tool and linked to the biological 
effects at the cellular level. The objective of this approach is 
to derive “biological weighting” functions that could be 
applied, for instance in hadrontherapy, to the experimentally 
known characteristics of the beam. 
In this talk, the multi-scale simulation tool will be presented, 
highlighting the improvements specifically made in this 
project with respect to other existing Monte Carlo simulation 
codes dedicated to radiobiology, for example the use of 
interaction cross-sections of DNA-like materials or 
fragmentation cross-sections to derive the probability of DNA 
breakage. Finally, taking into account only direct effects, the 
calculated double strand breaks in the simulated DNA 
molecule have been compared to experimental data of 53BP1 
foci formation, markers of DNA double strand breaks. The 
biological data were obtained in this project on endothelium 
cell population irradiated at the PTB ion microbeam facility 
using protons and alpha particles of different energies (i.e. 
different LET).  The microbeam irradiation was simulated 
from the macroscopic experimental parameters 
(uncertainties linked to the beam characteristics, to position 
and shape of cell nuclei, etc.) to the nanometric energy 
deposition in the DNA molecule. The results obtained allow 
defining the characteristics of the energy deposition clusters 
that can be at the origin of these radiation-induced damages. 
This work is carried out within the EMRP joint research 
project BioQuaRT. The EMRP is jointly funded by the EMRP 
participating countries within EURAMET and the European 
Union. 
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Radiotherapy using proton and carbon ion beams offers the 
advantages of excellent dose conformity for a maximised 
cell-killing within the treated tumour volume while 
minimizing at the same time radiation damage in normal 
tissue and, particularly, in critical organs.  
Within the recently finished COST Action MP1002 “Nanoscale 
insights into Ion Beam Cancer Therapy” (Nano-IBCT), a better 
understanding of the physical, chemical and biological 
mechanisms that lead to cell killing under ion beam 
irradiation was aspired. The goal was developing a multi-
scale approach by combining the unique experimental and 
theoretical expertise available within Europe to acquire 
greater insight into radiation damage at the nanoscopic and 
molecular level.  
The EMRP project SIB06 “Biologically weighted quantities in 
radiotherapy” (BioQuaRT) aims at laying the foundations for 
new radiation quantities. These should allow a transparent 
separation of physical processes (dependent on modality) 
from the biological ones (independent of modality) that 
contribute to the relative biological effectiveness. A 
metrological multi-scale approach is used for the 
characterisation of particle track structure at length scales 
from nanometers (diameter of the DNA double helix) to 
micrometers (dimension of the cell nucleus) [1]. This 
approach builds on the development of detector systems and 
an integrated numerical simulation tool. 
The potential of the two approaches for underpinning the 
exploitation of the full potential of ion beam modalities will 
be discussed.  
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Traditional normal tissue complication probability (NTCP) 
models in radiotherapy have been focusing on radiation dose-
effect relationships and attempts to extract information 
about which dose metrics are most important in predicting 
toxicity. The QUANTEC papers are probably the most well 
known effort to this end. However, the importance of 
incorporating clinical factors in NTCP models is being 
increasingly recognized - and was also discussed in the 
QUANTEC papers. 
The talk will review some of the examples of clinical factors 
that have been shown to inform NTCP models in different 
organs. A method to estimate the impact of a clinical risk 
factor on a dosimetric treatment planning objective will be 
shown. Several methods to combine clinical and dosimetric 
factors in the analysis of clinical outcome data will then be 
presented and reviewed with references for further study. 
The risks associated with the addition of multiple additional 
fitting parameters in the NTCP models will be discussed and 
the generalizability of the multifactorial NTCP models will be 
investigated from published examples. 
Example of a dose-only model of risk of radiation pneumonitis 
(top) compared to an NTCP model based on dose and clinical 
risk factors (bottom) evaluated on a dataset that is 
independent of the model fits. The curves show the observed 
cumulative incidence in a high risk group compared to a low 
risk group according to the model. Figure from Appelt et 
al, Acta Oncologica, 53 (2014), 605-12.  
